All In Biotech

Drug Trial Radar · NCT05092958

Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study

MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy in Patients With Metastatic Urothelial Cancer

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 654 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

654

Planned (sponsor's estimate)

Start

Jun 3, 2022

Primary completion

Jul 15, 2029

Study completion Jul 15, 2029

Sponsor

Sponsor type
NIH
First posted
Oct 26, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase III trial compares the effect of adding cabozantinib to avelumab versus avelumab alone in treating patients with urothelial cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib and avelumab together may further shrink the cancer or prevent it from returning/progressing.

Conditions

  • Advanced Bladder Urothelial Carcinoma
  • Advanced Renal Pelvis Urothelial Carcinoma
  • Advanced Ureter Urothelial Carcinoma
  • Advanced Urethral Urothelial Carcinoma
  • Metastatic Bladder Urothelial Carcinoma
  • Metastatic Renal Pelvis Urothelial Carcinoma
  • Metastatic Ureter Urothelial Carcinoma
  • Metastatic Urethral Urothelial Carcinoma
  • Stage III Bladder Cancer AJCC v8
  • Stage III Renal Pelvis and Ureter Cancer AJCC v8
  • Stage III Renal Pelvis Cancer AJCC v8
  • Stage III Ureter Cancer AJCC v8
  • Stage III Urethral Cancer AJCC v8
  • Stage IV Bladder Cancer AJCC v8
  • Stage IV Renal Pelvis and Ureter Cancer AJCC v8
  • Stage IV Renal Pelvis Cancer AJCC v8
  • Stage IV Ureter Cancer AJCC v8
  • Stage IV Urethral Cancer AJCC v8

Interventions

  • AvelumabDrug

    Given IV

  • Biospecimen CollectionProcedure

    Undergo collection of blood and urine samples

  • Bone ScanProcedure

    Undergo bone scan

  • Cabozantinib S-malateDrug

    Given PO

  • Computed TomographyProcedure

    Undergo CT

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • Quality-of-Life AssessmentOther

    Ancillary studies

  • Questionnaire AdministrationOther

    Ancillary studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival (OS)Time frame: Time from randomization until death due to any cause, assessed up to 5 years

Locations

275 sites in 2 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Hospital in Arizona

    Phoenix, Arizona

  • Sutter Auburn Faith Hospital

    Auburn, California

  • Alta Bates Summit Medical Center-Herrick Campus

    Berkeley, California

  • Palo Alto Medical Foundation-Fremont

    Fremont, California

  • Memorial Medical Center

    Modesto, California

  • Palo Alto Medical Foundation-Camino Division

    Mountain View, California

  • Palo Alto Medical Foundation Health Care

    Palo Alto, California

  • Sutter Roseville Medical Center

    Roseville, California

  • Sutter Medical Center Sacramento

    Sacramento, California

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California

  • California Pacific Medical Center-Pacific Campus

    San Francisco, California

  • Palo Alto Medical Foundation-Santa Cruz

    Santa Cruz, California

  • Palo Alto Medical Foundation-Sunnyvale

    Sunnyvale, California

  • Sutter Solano Medical Center/Cancer Center

    Vallejo, California

  • Beebe South Coastal Health Campus

    Millville, Delaware

  • Helen F Graham Cancer Center

    Newark, Delaware

  • Medical Oncology Hematology Consultants PA

    Newark, Delaware

  • Beebe Health Campus

    Rehoboth Beach, Delaware

  • MedStar Washington Hospital Center

    Washington D.C., District of Columbia

  • UF Health Cancer Institute - Gainesville

    Gainesville, Florida

  • Mayo Clinic in Florida

    Jacksonville, Florida

  • Cleveland Clinic-Weston

    Weston, Florida

  • Rush-Copley Medical Center

    Aurora, Illinois

  • Advocate Good Shepherd Hospital

    Barrington, Illinois

  • Illinois CancerCare-Bloomington

    Bloomington, Illinois

  • Illinois CancerCare-Canton

    Canton, Illinois

  • Illinois CancerCare-Carthage

    Carthage, Illinois

  • Centralia Oncology Clinic

    Centralia, Illinois

  • Northwestern University

    Chicago, Illinois

  • Rush MD Anderson Cancer Center

    Chicago, Illinois

  • University of Illinois

    Chicago, Illinois

  • Advocate Illinois Masonic Medical Center

    Chicago, Illinois

  • AMG Crystal Lake - Oncology

    Crystal Lake, Illinois

  • Carle at The Riverfront

    Danville, Illinois

  • Cancer Care Specialists of Illinois - Decatur

    Decatur, Illinois

  • Northwestern Medicine Cancer Center Kishwaukee

    DeKalb, Illinois

  • Illinois CancerCare-Dixon

    Dixon, Illinois

  • Advocate Good Samaritan Hospital

    Downers Grove, Illinois

  • Carle Physician Group-Effingham

    Effingham, Illinois

  • Crossroads Cancer Center

    Effingham, Illinois

Showing 40 of 275 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.